- An official NMPA public record supports approval of ivonescimab with pemetrexed and carboplatin for the defined China indication.
- Approval for populations, treatment lines, combinations, or jurisdictions outside the regulator-defined scope
- Comparative superiority or outcome claims beyond the cited evidence
- NMPA approval label or official indication update
- Official regulator safety, suspension, withdrawal, or correction notice
- Authoritative source correction tied to the cited approval
- Manufacturer commercial copy
- Media summary without a regulator record
- Trial result alone without a regulatory action
- Approval in another jurisdiction
- Unverified drug database entry
GAP_ID
OEG-ONC-002
CASE_ID
SE-ONC-NSQNSCLC-CN-001
CLAIM
Ivonescimab with pemetrexed and carboplatin was approved in China for the defined post-EGFR-TKI non-squamous NSCLC indication.
CURRENT STATE
SUPPORTED
SCOPE
Population-level regulatory status in China for EGFR-mutated locally advanced or metastatic non-squamous NSCLC progressing after EGFR-TKI; other populations, treatment lines, combinations, and jurisdictions are outside this claim.
EVIDENCE CUTOFF
2026-09-28
WHAT IS ESTABLISHED
WHAT IS NOT ESTABLISHED
WHAT WOULD CHANGE THIS
An official regulator record that changes, narrows, expands, suspends, withdraws, or corrects the approval status, label, combination, population, or treatment-line scope; or an authoritative correction or retraction of the cited regulatory source.
ACCEPTABLE SOURCES
NON-QUALIFYING SOURCES